Sign in

CIK 0001520262 · Large accelerated filer

Alkermes plc.

Sign in to watch
Ticker
ALKS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
981007018
Phone
00-353-1-772-8000
Business address
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
Former names
ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
  1. 4 Planned sale EVP, CLO, Alkermes, Inc. sold 2,035 shares at $46.17 ($93,956)
  2. 4 Shares withheld for taxes SVP, Chief Financial Officer gave up 4,069 shares (to pay taxes)
  3. 4 Derivatives Options or other derivatives
  4. 4 Planned sale EVP, CLO, Alkermes, Inc. sold 2,034 shares at $41.03 ($83,455)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Planned sale EVP, CLO, Alkermes, Inc. sold 2,034 shares at $48.01 ($97,652)
  7. 4 Planned sale EVP R&D, Chief Medical Officer sold 9,000 shares at $46.99 ($422,874)
  8. 4 Planned sale SVP, Chief Commercial Officer sold 7,576 shares at an average $49.23 ($372,937)
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market sale Director sold 44,472 shares at $50.35 ($2,239,076)
  11. 4 Planned sale EVP R&D, Chief Medical Officer sold 9,000 shares at $48.58 ($437,220)
  12. 4 Planned sale EVP, CLO, Alkermes, Inc. sold 2,034 shares at $48.58 ($98,812)
  13. 4 Planned sale EVP, CLO, Alkermes, Inc. sold 2,034 shares at $54.03 ($109,897)
  14. 4 Planned sale EVP R&D, Chief Medical Officer sold 9,000 shares at an average $51.51 ($463,621)
  15. 4 Planned sale Director sold 2,000 shares at $45.10 ($90,200)
  16. 4 Planned sale EVP, CLO, Alkermes, Inc. sold 2,034 shares at $43.05 ($87,564)
  17. 4 Planned sale EVP R&D, Chief Medical Officer sold 9,000 shares at $41.67 ($375,044)
  18. 4 Open-market sale VP, Finance (Interim PAO) sold 16,217 shares at $42.36 ($687,007)
  19. 4 Shares withheld for taxes Director gave up 1,475 shares (to pay taxes)
  20. 4 Shares withheld for taxes Director gave up 1,475 shares (to pay taxes)

Page 1 of 67 · 1,323 filings